Crescent Biopharma, Inc. (CBIO) stock
CBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 10/30
$14.15−0.22 (-1.53%)
Close on Nov 13, 2026Market cap $525.59MP/E –Yield –
Earnings
Crescent Biopharma's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
Feb 25, 2027
Q4 FY2026 · estimated, before the open
Revenue, Q3 FY2026
$3.12M
EPS, Q3 FY2026
-$0.90
-$1.27 a year earlier
Latest guidance
None
No outlook given in releases
Quarterly results
Revenue and earnings per share from each of Crescent Biopharma's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Feb 25, 2027Expected | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 12, 2026after the close | $3.12M | – | -$0.90 | Release |
| Q2 FY2026ended Jun 30, 2026 | Jul 30, 2026before the open | – | – | -$0.74 | Release |
| Q1 FY2026ended Mar 31, 2026 | Apr 29, 2026after the close | $1.00M | – | -$0.70 | Release |
| Q4 FY2025ended Dec 31, 2025 | Feb 26, 2026before the open | $10.80M | – | -$4.01 | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 6, 2025before the open | – | – | -$1.27 | Release |
| Q2 FY2025ended Jun 30, 2025 | Jul 31, 2025before the open | – | – | – | Release |
| Q1 FY2025ended Mar 31, 2025 | Jun 18, 2025after the close | – | – | – | Release |
| Q1 FY2024ended Mar 31, 2024 | May 6, 2024after the close | – | – | – | Release |
| Q4 FY2023ended Dec 31, 2023 | Mar 27, 2024before the open | – | – | – | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 3, 2023before the open | – | – | – | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 2, 2023before the open | – | – | – | Release |
| Q1 FY2023ended Mar 31, 2023 | May 3, 2023before the open | – | – | – | Release |
| Q4 FY2022ended Dec 31, 2022 | Mar 29, 2023before the open | – | – | – | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 9, 2022before the open | – | – | – | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 3, 2022before the open | – | – | – | Release |
| Q1 FY2022ended Mar 31, 2022 | Apr 28, 2022before the open | – | – | – | Release |
| Q4 FY2021ended Dec 31, 2021 | Mar 3, 2022before the open | – | – | – | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 2, 2021before the open | – | – | – | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 5, 2021before the open | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | May 3, 2021before the open | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Mar 2, 2021after the close | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Nov 6, 2020before the open | – | – | – | Filing |
| Q2 FY2020ended Jun 30, 2020 | Jul 31, 2020before the open | – | – | – | Filing |
| Q1 FY2020ended Mar 31, 2020 | May 1, 2020before the open | – | – | – | Filing |
| Q4 FY2019ended Dec 31, 2019 | Feb 28, 2020during market hours | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
Crescent Biopharma has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When Crescent Biopharma puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases Crescent Biopharma filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- News
- News
- Results
- Results
- Update
- Update
- Update
- Results
- Results
- Results
- Results
- Results
- Update
See a number that looks wrong?